Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum

Melichar B, Hyspler R, Dragounová E, Dvorák J, Kalábová H, Tichá A

. 2007 ; (7) : 155.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc10001000

BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated with paclitaxel or platinum. METHODS: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in different subgroups. RESULTS: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed, but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious (grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p = 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were significantly increased in patients with serious toxicity. CONCLUSION: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious toxicity.

Citace poskytuje Crossref.org

000      
00000naa 2200000 a 4500
001      
bmc10001000
003      
CZ-PrNML
005      
20111210154841.0
008      
100117s2007 xxk e eng||
009      
AR
024    __
$a 10.1186/1471-2407-7-155 $2 doi
035    __
$a (PubMed)17688683
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853
245    10
$a Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum / $c Melichar B, Hyspler R, Dragounová E, Dvorák J, Kalábová H, Tichá A
314    __
$a Department of Oncology & Radiotherapy, Charles University Medical School & Teaching Hospital, Sokolská 581, Building 23, 500 05, Hradec Králové, Czech Republic. melichar@fnhk.cz
520    9_
$a BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated with paclitaxel or platinum. METHODS: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in different subgroups. RESULTS: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed, but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious (grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p = 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were significantly increased in patients with serious toxicity. CONCLUSION: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious toxicity.
650    _2
$a financování organizované $7 D005381
650    _2
$a adenokarcinom $x farmakoterapie $x metabolismus $x patologie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x aplikace a dávkování $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
650    _2
$a karboplatina $x aplikace a dávkování $7 D016190
650    _2
$a permeabilita buněčné membrány $x účinky léků $7 D002463
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální trakt $x metabolismus $7 D041981
650    _2
$a lidé $7 D006801
650    _2
$a intestinální absorpce $x účinky léků $7 D007408
650    _2
$a laktulosa $x metabolismus $7 D007792
650    _2
$a mannitol $x metabolismus $7 D008353
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory glandulární a epitelové $x farmakoterapie $x metabolismus $x patologie $7 D009375
650    _2
$a nádory vaječníků $x farmakoterapie $x metabolismus $x patologie $7 D010051
650    _2
$a paclitaxel $x aplikace a dávkování $7 D017239
650    _2
$a sacharasa $x metabolismus $7 D013393
650    _2
$a xylosa $x metabolismus $7 D014994
700    1_
$a Hyšpler, Radomír, $d 1972- $7 nlk20040155091
700    1_
$a Dragounová, Emanuela $7 xx0081952
700    1_
$a Dvořák, Josef, $d 1966- $7 xx0072583
700    1_
$a Kalábová, Hana. $7 xx0240731
700    1_
$a Tichá, Alena, $d 1976- $7 xx0076494
773    0_
$w MED00008171 $t BMC cancer $g č. 7 (2007), s. 155 $x 1471-2407
910    __
$a ABA008 $b x $y 8
990    __
$a 20100114083259 $b ABA008
991    __
$a 20100215120121 $b ABA008
999    __
$a ok $b bmc $g 703728 $s 566170
BAS    __
$a 3
BMC    __
$a 2007 $c 7 $d 155 $i 1471-2407 $m BMC cancer $x MED00008171
LZP    __
$a 2010-b1/vtme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...